AR and prostate cancer: Since light-triggered therapies could potentially have a significantly positive impact on the treatment of hormone-sensitive cancers, this targeted bimodal oxime conjugate was evaluated on prostatic cancer cell lines in vitro, using an AR-positive cell line (LNCaP) and an AR-negative/positive cell line (PC-3) [246].